AMPH — Amphastar Pharmaceuticals, Inc.
Is AMPH overbought or oversold? Here is the current MarketMoodz read.
Amphastar Pharmaceuticals, Inc. (AMPH) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $29.10. The rating moved from Overbought to Neutral on November 12, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$29.10
- Last changeMoved from Overbought to Neutral on November 12, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
AI analysis
Amphastar exhibits the characteristics of a mid‑tier specialty and sterile injectable manufacturer: a defensible manufacturing footprint and recurring hospital/outpatient demand, offset by exposure to generic pricing pressure and regulatory inspection risk. Near-term catalysts are limited, making performance dependent on execution around product launches, quality/compliance outcomes, and distributor channel flows. Market context favors defensive large-cap pharma, which may limit sector rotational support for smaller specialty names absent clear positive catalysts.
Key factors
- Established sterile-injectable and specialty products portfolio with recurring revenue streams from hospital and outpatient channels
- Manufacturing footprint and capacity for sterile injectables creates a barrier to new entrants but requires ongoing CAPEX and regulatory compliance
- Pricing pressure in generics and competitive dynamics could compress margins over time
- Distributor and specialty pharmacy flow themes may support sustained prescription volumes for injectable and specialty channels
- Limited visible near-term catalysts from filings or social sentiment; earnings and product approvals remain primary upside triggers
- Moderate balance sheet and cash generation historically support operations but growth depends on successful product launches or licensing
Risks
- Regulatory and FDA inspection risk tied to sterile manufacturing and product quality; remediation can be costly and disruptive
- Revenue concentration by product or channel that could amplify impact from single-product setbacks or competitive entries
- Generic pricing erosion and reimbursement pressures, including potential impacts from Medicare/insurer policy tightening
- Supply-chain or input-cost shocks that increase manufacturing costs or constrain production
- Litigation or product liability exposures common in injectable/medical-product businesses
- Low visibility in social and sell-side sentiment increases the risk of abrupt trading moves on unexpected news
See today's live rating, score and targets
Members see the live hourly rating for AMPH — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.